| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Telomere | 42 | 2025 | 220 | 9.520 |
Why?
|
| Telomerase | 23 | 2023 | 157 | 4.630 |
Why?
|
| Anemia, Aplastic | 11 | 2025 | 62 | 3.080 |
Why?
|
| Dyskeratosis Congenita | 12 | 2022 | 23 | 2.980 |
Why?
|
| Saccharomyces cerevisiae Proteins | 12 | 2019 | 266 | 2.570 |
Why?
|
| Telomere Homeostasis | 9 | 2025 | 47 | 2.550 |
Why?
|
| Telomere-Binding Proteins | 11 | 2022 | 44 | 2.520 |
Why?
|
| Saccharomyces cerevisiae | 13 | 2019 | 405 | 2.510 |
Why?
|
| Telomere Shortening | 9 | 2022 | 34 | 1.820 |
Why?
|
| DNA-Binding Proteins | 14 | 2019 | 1965 | 1.760 |
Why?
|
| DNA End-Joining Repair | 5 | 2019 | 38 | 1.600 |
Why?
|
| Germ-Line Mutation | 10 | 2025 | 375 | 1.580 |
Why?
|
| Antigens, Nuclear | 7 | 2018 | 52 | 1.380 |
Why?
|
| Bone Marrow Diseases | 5 | 2023 | 45 | 1.250 |
Why?
|
| Intellectual Disability | 5 | 2022 | 1086 | 1.160 |
Why?
|
| Serine Proteases | 2 | 2021 | 9 | 1.120 |
Why?
|
| Microcephaly | 4 | 2021 | 350 | 1.080 |
Why?
|
| DNA Repair | 8 | 2023 | 577 | 1.080 |
Why?
|
| Fetal Growth Retardation | 3 | 2020 | 255 | 0.990 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 2 | 2018 | 4 | 0.980 |
Why?
|
| Mutation | 29 | 2024 | 6195 | 0.950 |
Why?
|
| Ku Autoantigen | 7 | 2018 | 21 | 0.940 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2025 | 754 | 0.840 |
Why?
|
| Mutation, Missense | 4 | 2019 | 935 | 0.820 |
Why?
|
| DNA, Circular | 1 | 2023 | 17 | 0.790 |
Why?
|
| Germ Cells | 2 | 2022 | 203 | 0.780 |
Why?
|
| DNA, Fungal | 4 | 2019 | 77 | 0.750 |
Why?
|
| Exoribonucleases | 2 | 2019 | 22 | 0.730 |
Why?
|
| DNA Damage | 4 | 2025 | 527 | 0.690 |
Why?
|
| Mutagenesis, Insertional | 2 | 2019 | 152 | 0.680 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2025 | 3425 | 0.680 |
Why?
|
| DNA Helicases | 4 | 2023 | 235 | 0.670 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2020 | 12 | 0.660 |
Why?
|
| Bone Marrow | 6 | 2021 | 314 | 0.640 |
Why?
|
| Ribosomal Proteins | 1 | 2020 | 71 | 0.640 |
Why?
|
| Child, Preschool | 28 | 2025 | 15081 | 0.610 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2025 | 738 | 0.610 |
Why?
|
| Pedigree | 8 | 2021 | 1717 | 0.600 |
Why?
|
| Exocrine Pancreatic Insufficiency | 2 | 2022 | 40 | 0.590 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2024 | 133 | 0.560 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 231 | 0.560 |
Why?
|
| Humans | 81 | 2025 | 132012 | 0.550 |
Why?
|
| Cell Line | 6 | 2023 | 2591 | 0.540 |
Why?
|
| Protein Binding | 11 | 2018 | 1673 | 0.520 |
Why?
|
| CD4-CD8 Ratio | 1 | 2017 | 11 | 0.520 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2016 | 142 | 0.520 |
Why?
|
| Antibodies, Antinuclear | 1 | 2017 | 31 | 0.510 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2016 | 34 | 0.510 |
Why?
|
| Hyperbilirubinemia | 1 | 2017 | 41 | 0.510 |
Why?
|
| Transaminases | 1 | 2017 | 36 | 0.500 |
Why?
|
| Inheritance Patterns | 2 | 2014 | 130 | 0.500 |
Why?
|
| Hepatitis | 1 | 2017 | 57 | 0.490 |
Why?
|
| Calreticulin | 1 | 2016 | 23 | 0.490 |
Why?
|
| Thrombopoietin | 1 | 2016 | 30 | 0.490 |
Why?
|
| Neoplasms | 5 | 2025 | 2968 | 0.480 |
Why?
|
| Thrombocythemia, Essential | 1 | 2016 | 33 | 0.480 |
Why?
|
| Janus Kinase 2 | 2 | 2016 | 140 | 0.460 |
Why?
|
| Adolescent | 28 | 2025 | 21004 | 0.460 |
Why?
|
| Tryptophan | 1 | 2015 | 85 | 0.450 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 837 | 0.440 |
Why?
|
| Cholestasis | 1 | 2017 | 165 | 0.430 |
Why?
|
| Lipomatosis | 1 | 2014 | 15 | 0.430 |
Why?
|
| Chromosomes, Fungal | 3 | 2011 | 49 | 0.420 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 194 | 0.420 |
Why?
|
| Siblings | 3 | 2014 | 204 | 0.410 |
Why?
|
| Child | 32 | 2025 | 26349 | 0.400 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 45 | 0.390 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 427 | 0.380 |
Why?
|
| Neutropenia | 3 | 2019 | 206 | 0.380 |
Why?
|
| MicroRNAs | 1 | 2019 | 900 | 0.380 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 315 | 0.370 |
Why?
|
| Female | 40 | 2025 | 71358 | 0.370 |
Why?
|
| Immunosuppressive Agents | 3 | 2025 | 666 | 0.370 |
Why?
|
| Male | 38 | 2025 | 65403 | 0.360 |
Why?
|
| Phenotype | 13 | 2024 | 4539 | 0.360 |
Why?
|
| Hematologic Diseases | 2 | 2023 | 82 | 0.350 |
Why?
|
| Recombination, Genetic | 5 | 2013 | 423 | 0.340 |
Why?
|
| Syndrome | 5 | 2023 | 1169 | 0.340 |
Why?
|
| Cell Cycle Proteins | 4 | 2020 | 705 | 0.330 |
Why?
|
| Cellular Senescence | 2 | 2010 | 217 | 0.330 |
Why?
|
| Pancytopenia | 2 | 2023 | 40 | 0.320 |
Why?
|
| Flow Cytometry | 2 | 2025 | 773 | 0.310 |
Why?
|
| Penetrance | 2 | 2020 | 117 | 0.310 |
Why?
|
| Amino Acid Sequence | 5 | 2020 | 2423 | 0.290 |
Why?
|
| Proteins | 1 | 2014 | 1014 | 0.290 |
Why?
|
| Genomic Instability | 3 | 2022 | 249 | 0.290 |
Why?
|
| Young Adult | 12 | 2025 | 10118 | 0.290 |
Why?
|
| Exodeoxyribonucleases | 2 | 2009 | 50 | 0.290 |
Why?
|
| Chromosome Disorders | 1 | 2010 | 317 | 0.280 |
Why?
|
| Genetic Variation | 3 | 2020 | 1574 | 0.280 |
Why?
|
| Alleles | 7 | 2022 | 1708 | 0.280 |
Why?
|
| Leukemia, Myeloid | 2 | 2019 | 80 | 0.270 |
Why?
|
| Hematopoiesis | 2 | 2021 | 220 | 0.270 |
Why?
|
| DNA Replication | 3 | 2023 | 358 | 0.270 |
Why?
|
| Models, Theoretical | 1 | 2009 | 365 | 0.260 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1613 | 0.260 |
Why?
|
| Arteriovenous Fistula | 2 | 2018 | 55 | 0.260 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2025 | 100 | 0.260 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2024 | 590 | 0.250 |
Why?
|
| Adult | 20 | 2025 | 31736 | 0.250 |
Why?
|
| Protein Structure, Tertiary | 4 | 2020 | 719 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1360 | 0.240 |
Why?
|
| Infant | 16 | 2025 | 13336 | 0.230 |
Why?
|
| Pulmonary Veins | 2 | 2018 | 169 | 0.230 |
Why?
|
| Immunoprecipitation | 2 | 2019 | 191 | 0.230 |
Why?
|
| Granulocytes | 1 | 2025 | 69 | 0.230 |
Why?
|
| Benzoates | 1 | 2025 | 25 | 0.230 |
Why?
|
| Hydrazines | 1 | 2025 | 30 | 0.230 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2020 | 635 | 0.230 |
Why?
|
| Ethosuximide | 1 | 2025 | 13 | 0.220 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 513 | 0.220 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2025 | 51 | 0.220 |
Why?
|
| Primary Myelofibrosis | 2 | 2018 | 54 | 0.220 |
Why?
|
| Cyclosporine | 3 | 2025 | 131 | 0.220 |
Why?
|
| Pulmonary Artery | 2 | 2018 | 441 | 0.210 |
Why?
|
| Silent Information Regulator Proteins, Saccharomyces cerevisiae | 4 | 2017 | 9 | 0.210 |
Why?
|
| DNA | 2 | 2014 | 1440 | 0.210 |
Why?
|
| Lymphocytes | 1 | 2025 | 359 | 0.200 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2018 | 209 | 0.200 |
Why?
|
| Osteochondrodysplasias | 2 | 2019 | 69 | 0.200 |
Why?
|
| HeLa Cells | 3 | 2023 | 694 | 0.200 |
Why?
|
| DNA Ligases | 1 | 2002 | 15 | 0.190 |
Why?
|
| Gene Order | 2 | 2014 | 82 | 0.190 |
Why?
|
| Nephrocalcinosis | 1 | 2022 | 9 | 0.190 |
Why?
|
| Hypercalcemia | 1 | 2022 | 42 | 0.190 |
Why?
|
| Biology | 1 | 2022 | 25 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2025 | 358 | 0.190 |
Why?
|
| Hydroxyurea | 1 | 2023 | 88 | 0.180 |
Why?
|
| Cell Division | 2 | 2003 | 720 | 0.180 |
Why?
|
| Anticonvulsants | 1 | 2025 | 391 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 226 | 0.180 |
Why?
|
| Inflammation | 2 | 2020 | 1502 | 0.180 |
Why?
|
| GATA2 Transcription Factor | 1 | 2021 | 46 | 0.180 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 1299 | 0.180 |
Why?
|
| UDPglucose 4-Epimerase | 1 | 2021 | 7 | 0.180 |
Why?
|
| Galactosemias | 1 | 2021 | 14 | 0.170 |
Why?
|
| Antilymphocyte Serum | 2 | 2019 | 44 | 0.170 |
Why?
|
| Leukoplakia, Oral | 1 | 2021 | 2 | 0.170 |
Why?
|
| Receptor, EphB2 | 1 | 2021 | 8 | 0.170 |
Why?
|
| Growth Disorders | 1 | 2022 | 184 | 0.170 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 29 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 418 | 0.170 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 3535 | 0.170 |
Why?
|
| Nails | 1 | 2021 | 21 | 0.170 |
Why?
|
| Aging | 2 | 2022 | 1270 | 0.170 |
Why?
|
| Metabolic Diseases | 1 | 2022 | 140 | 0.170 |
Why?
|
| Central Nervous System Cysts | 1 | 2020 | 12 | 0.170 |
Why?
|
| Anemia, Macrocytic | 1 | 2020 | 7 | 0.170 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2020 | 7 | 0.170 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2021 | 50 | 0.170 |
Why?
|
| Riboflavin Deficiency | 1 | 2020 | 8 | 0.170 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2019 | 233 | 0.160 |
Why?
|
| Dimerization | 3 | 2007 | 139 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2025 | 2478 | 0.160 |
Why?
|
| Retrospective Studies | 9 | 2025 | 17739 | 0.160 |
Why?
|
| Riboflavin | 1 | 2020 | 31 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 2 | 2020 | 590 | 0.160 |
Why?
|
| Muscle Spasticity | 1 | 2020 | 55 | 0.160 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2020 | 58 | 0.160 |
Why?
|
| Leukoencephalopathies | 1 | 2020 | 63 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 611 | 0.150 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2019 | 40 | 0.150 |
Why?
|
| Gene Deletion | 2 | 2021 | 772 | 0.150 |
Why?
|
| Nuclear Proteins | 5 | 2021 | 1226 | 0.150 |
Why?
|
| Calcinosis | 1 | 2020 | 187 | 0.150 |
Why?
|
| Ataxia | 1 | 2020 | 169 | 0.150 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.150 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 60 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 155 | 0.140 |
Why?
|
| Metal Metabolism, Inborn Errors | 1 | 2018 | 7 | 0.140 |
Why?
|
| Telangiectasis | 1 | 2018 | 9 | 0.140 |
Why?
|
| Biological Variation, Population | 1 | 2018 | 28 | 0.140 |
Why?
|
| Retinal Diseases | 1 | 2020 | 151 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 212 | 0.140 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2019 | 70 | 0.140 |
Why?
|
| Phosphorylation | 2 | 2020 | 1571 | 0.140 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 125 | 0.140 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 81 | 0.140 |
Why?
|
| Arthralgia | 1 | 2018 | 77 | 0.140 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 137 | 0.140 |
Why?
|
| DNA Mutational Analysis | 3 | 2014 | 804 | 0.130 |
Why?
|
| Metabolome | 1 | 2020 | 328 | 0.130 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 166 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2021 | 550 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2019 | 659 | 0.130 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 23 | 0.130 |
Why?
|
| Models, Molecular | 2 | 2013 | 1063 | 0.130 |
Why?
|
| Vesicular Transport Proteins | 1 | 2018 | 141 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 279 | 0.130 |
Why?
|
| Molecular Docking Simulation | 1 | 2017 | 147 | 0.130 |
Why?
|
| Protein Isoforms | 1 | 2018 | 420 | 0.130 |
Why?
|
| Hypergammaglobulinemia | 1 | 2017 | 11 | 0.130 |
Why?
|
| Retina | 1 | 2020 | 462 | 0.130 |
Why?
|
| Acute Disease | 2 | 2017 | 1153 | 0.130 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 323 | 0.130 |
Why?
|
| Transcription Factors | 3 | 2023 | 2444 | 0.130 |
Why?
|
| NF-kappa B | 1 | 2019 | 450 | 0.120 |
Why?
|
| Patient Selection | 1 | 2020 | 726 | 0.120 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 51 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 312 | 0.120 |
Why?
|
| Androgens | 1 | 2018 | 272 | 0.120 |
Why?
|
| Platelet Count | 1 | 2016 | 140 | 0.120 |
Why?
|
| Liver Failure | 1 | 2017 | 99 | 0.120 |
Why?
|
| Quinolinic Acid | 1 | 2015 | 10 | 0.120 |
Why?
|
| Amino Acid Transport Systems | 1 | 2015 | 10 | 0.110 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 81 | 0.110 |
Why?
|
| Family | 2 | 2016 | 593 | 0.110 |
Why?
|
| Amino Acid Substitution | 2 | 2020 | 410 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2024 | 1133 | 0.110 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 317 | 0.110 |
Why?
|
| Galactose | 1 | 2015 | 53 | 0.110 |
Why?
|
| Patients | 1 | 2016 | 122 | 0.110 |
Why?
|
| NAD | 1 | 2015 | 50 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2018 | 364 | 0.110 |
Why?
|
| Seizures | 1 | 2020 | 891 | 0.110 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 180 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 1746 | 0.110 |
Why?
|
| Bleomycin | 1 | 2015 | 119 | 0.110 |
Why?
|
| Leprosy, Tuberculoid | 1 | 2014 | 7 | 0.110 |
Why?
|
| Actins | 1 | 2017 | 317 | 0.110 |
Why?
|
| Molluscum Contagiosum | 1 | 2014 | 11 | 0.110 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2014 | 13 | 0.110 |
Why?
|
| Prognosis | 6 | 2020 | 4959 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 362 | 0.110 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 179 | 0.110 |
Why?
|
| Neutrophils | 1 | 2016 | 370 | 0.110 |
Why?
|
| Enzyme Activation | 1 | 2015 | 590 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 212 | 0.110 |
Why?
|
| Mucous Membrane | 1 | 2014 | 88 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 46 | 0.110 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 160 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 639 | 0.100 |
Why?
|
| Granuloma | 1 | 2014 | 63 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 583 | 0.100 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2014 | 106 | 0.100 |
Why?
|
| Models, Biological | 3 | 2009 | 1395 | 0.100 |
Why?
|
| Abdomen | 1 | 2014 | 133 | 0.100 |
Why?
|
| Animals | 9 | 2021 | 34246 | 0.100 |
Why?
|
| Threonine | 1 | 2012 | 62 | 0.100 |
Why?
|
| Infant, Newborn | 4 | 2020 | 8609 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2013 | 283 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2013 | 150 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 136 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 272 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 570 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2020 | 2871 | 0.090 |
Why?
|
| Serine | 1 | 2012 | 161 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 346 | 0.090 |
Why?
|
| Base Sequence | 3 | 2011 | 2783 | 0.090 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 53 | 0.090 |
Why?
|
| Middle Aged | 9 | 2025 | 28937 | 0.090 |
Why?
|
| Telomeric Repeat Binding Protein 1 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Glutamine | 1 | 2012 | 204 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 495 | 0.090 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 60 | 0.090 |
Why?
|
| Skin | 1 | 2014 | 553 | 0.090 |
Why?
|
| Homozygote | 1 | 2013 | 548 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 300 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2021 | 4698 | 0.080 |
Why?
|
| Genes, Dominant | 1 | 2011 | 253 | 0.080 |
Why?
|
| HLA Antigens | 2 | 2022 | 226 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1308 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2010 | 60 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 39 | 0.080 |
Why?
|
| Abdominal Neoplasms | 1 | 2010 | 31 | 0.080 |
Why?
|
| Mice | 6 | 2021 | 18381 | 0.080 |
Why?
|
| Leukemia | 2 | 2012 | 375 | 0.080 |
Why?
|
| Glioma | 1 | 2014 | 500 | 0.080 |
Why?
|
| Saccharomyces | 1 | 2009 | 9 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 388 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2009 | 598 | 0.080 |
Why?
|
| Werner Syndrome Helicase | 1 | 2009 | 2 | 0.080 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 19 | 0.080 |
Why?
|
| Receptors, Transferrin | 1 | 2009 | 12 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2025 | 3094 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2010 | 155 | 0.080 |
Why?
|
| Fibrosarcoma | 1 | 2009 | 24 | 0.080 |
Why?
|
| HCT116 Cells | 1 | 2009 | 60 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2014 | 976 | 0.080 |
Why?
|
| Chromosome Segregation | 1 | 2009 | 71 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 41 | 0.080 |
Why?
|
| Genes, Essential | 1 | 2009 | 43 | 0.070 |
Why?
|
| Dacarbazine | 1 | 2009 | 94 | 0.070 |
Why?
|
| RecQ Helicases | 1 | 2009 | 63 | 0.070 |
Why?
|
| Liver | 1 | 2017 | 1805 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 98 | 0.070 |
Why?
|
| Fungal Proteins | 1 | 2009 | 132 | 0.070 |
Why?
|
| Plasmids | 2 | 2014 | 455 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2009 | 155 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 51 | 0.070 |
Why?
|
| Exome | 3 | 2018 | 1079 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2025 | 13022 | 0.070 |
Why?
|
| North America | 2 | 2021 | 260 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 778 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 5292 | 0.070 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2007 | 62 | 0.060 |
Why?
|
| Cell Survival | 1 | 2009 | 850 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2008 | 147 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2007 | 100 | 0.060 |
Why?
|
| Gene Expression | 1 | 2011 | 1506 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 238 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 566 | 0.060 |
Why?
|
| Genes, cdc | 1 | 2006 | 24 | 0.060 |
Why?
|
| Meningioma | 1 | 2008 | 137 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 652 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 1271 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2007 | 419 | 0.060 |
Why?
|
| Hair Diseases | 1 | 2005 | 14 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 208 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 555 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2022 | 5124 | 0.060 |
Why?
|
| Translocation, Genetic | 2 | 2021 | 350 | 0.060 |
Why?
|
| RNA, Untranslated | 1 | 2005 | 111 | 0.060 |
Why?
|
| Genotype | 2 | 2017 | 2655 | 0.050 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2004 | 40 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2008 | 385 | 0.050 |
Why?
|
| Oligonucleotide Probes | 1 | 2004 | 87 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2024 | 157 | 0.050 |
Why?
|
| Yeasts | 1 | 2003 | 42 | 0.050 |
Why?
|
| Protein Structure, Quaternary | 1 | 2003 | 93 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 1260 | 0.050 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2023 | 2 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2003 | 156 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2006 | 752 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2003 | 282 | 0.050 |
Why?
|
| DNA Ligase ATP | 1 | 2002 | 11 | 0.050 |
Why?
|
| Species Specificity | 1 | 2003 | 497 | 0.050 |
Why?
|
| HLA-B Antigens | 1 | 2022 | 30 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 3863 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 622 | 0.050 |
Why?
|
| Genetic Counseling | 2 | 2016 | 241 | 0.050 |
Why?
|
| Binding Sites | 3 | 2017 | 1148 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 115 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 1173 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2021 | 121 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2021 | 49 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2003 | 735 | 0.040 |
Why?
|
| Fetal Hemoglobin | 1 | 2021 | 27 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 2021 | 42 | 0.040 |
Why?
|
| Glycolipids | 1 | 2021 | 33 | 0.040 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2021 | 36 | 0.040 |
Why?
|
| Leukocytes | 2 | 2017 | 211 | 0.040 |
Why?
|
| Biomarkers | 1 | 2010 | 3418 | 0.040 |
Why?
|
| Interferons | 1 | 2021 | 136 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 934 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1916 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2020 | 51 | 0.040 |
Why?
|
| Ribosomes | 1 | 2021 | 124 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2020 | 71 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2021 | 143 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 127 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2020 | 78 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2024 | 385 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2020 | 366 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2020 | 143 | 0.040 |
Why?
|
| Genomics | 2 | 2019 | 1630 | 0.040 |
Why?
|
| Heterozygote | 2 | 2014 | 728 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2019 | 1105 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 432 | 0.040 |
Why?
|
| Eukaryotic Cells | 1 | 1998 | 30 | 0.040 |
Why?
|
| Risk Factors | 1 | 2013 | 11011 | 0.040 |
Why?
|
| De Lange Syndrome | 1 | 2018 | 44 | 0.040 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2018 | 17 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2014 | 1219 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2018 | 93 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 366 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2019 | 2946 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 299 | 0.030 |
Why?
|
| Consanguinity | 1 | 2018 | 119 | 0.030 |
Why?
|
| Education | 1 | 2018 | 113 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 134 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 277 | 0.030 |
Why?
|
| Colon | 1 | 2020 | 361 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2017 | 68 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 838 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 314 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 340 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 751 | 0.030 |
Why?
|
| Zebrafish | 1 | 2019 | 428 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 309 | 0.030 |
Why?
|
| Apoptosis | 1 | 2003 | 1863 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1473 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 92 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 577 | 0.030 |
Why?
|
| Perfusion | 1 | 2017 | 212 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 563 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 765 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 140 | 0.030 |
Why?
|
| Hypoxia | 1 | 2017 | 246 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 21 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1253 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 602 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 866 | 0.030 |
Why?
|
| RNA | 1 | 2017 | 530 | 0.030 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2014 | 55 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1524 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1080 | 0.030 |
Why?
|
| Sumoylation | 1 | 2014 | 41 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1996 | 249 | 0.030 |
Why?
|
| Lysine | 1 | 2014 | 165 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2018 | 1023 | 0.020 |
Why?
|
| Aged | 3 | 2016 | 21291 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2014 | 197 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1409 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 3002 | 0.020 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 835 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2012 | 194 | 0.020 |
Why?
|
| Anemia, Myelophthisic | 1 | 2012 | 2 | 0.020 |
Why?
|
| Reticulin | 1 | 2012 | 8 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2012 | 15 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2018 | 974 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2016 | 564 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2012 | 65 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2148 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 4688 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2012 | 32 | 0.020 |
Why?
|
| S Phase | 1 | 2011 | 73 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2012 | 172 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 612 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 793 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1028 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 282 | 0.020 |
Why?
|
| Eosinophilia | 1 | 2012 | 109 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 289 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 630 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2702 | 0.020 |
Why?
|
| Spores, Fungal | 1 | 2009 | 14 | 0.020 |
Why?
|
| Sirtuin 2 | 1 | 2009 | 13 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 45 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2009 | 48 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2009 | 50 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2009 | 254 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2009 | 98 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 240 | 0.020 |
Why?
|
| Lung | 1 | 2017 | 1578 | 0.020 |
Why?
|
| Vincristine | 1 | 2009 | 194 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2578 | 0.020 |
Why?
|
| Leg | 1 | 2009 | 124 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2009 | 471 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 433 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2009 | 307 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1620 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1236 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3645 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 874 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 440 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1066 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1612 | 0.020 |
Why?
|
| Simian virus 40 | 1 | 1987 | 190 | 0.020 |
Why?
|
| RNA, Ribosomal, 5.8S | 1 | 2005 | 4 | 0.010 |
Why?
|
| Cartilage | 1 | 2005 | 54 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2005 | 48 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 2228 | 0.010 |
Why?
|
| RNA Stability | 1 | 2005 | 75 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6932 | 0.010 |
Why?
|
| Embryonic Development | 1 | 2005 | 224 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 635 | 0.010 |
Why?
|
| United States | 1 | 2019 | 11838 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2005 | 579 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 3708 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1005 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3132 | 0.010 |
Why?
|
| Cytokines | 1 | 2005 | 1355 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1847 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1996 | 120 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1996 | 216 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1996 | 98 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1996 | 101 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1987 | 351 | 0.000 |
Why?
|
| DNA, Viral | 1 | 1987 | 452 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1987 | 1398 | 0.000 |
Why?
|